Dan hartung

Professor. Oregon State University

Pharmaceutical health services researcher

Midwest enthusiast

[Dan hartung @landgrantdan]

Bausch Health leaves Medicaid and 340B programs as drugmakers face changing calculus on pricing https://t.co/XILD830fuH via @statnews

Perhaps this could signal a wider pull back from all federal programs, as Xifaxan has also been selected for Medicare drug price negotiations.

[Dan hartung @landgrantdan]

@PittCP3 Thanks so much for hosting me. From perogies to pharmaceutical policy, I enjoyed my time in pittsburgh so much!

[Dan hartung @landgrantdan]

@ASayedMD It's crazy that acthar is still surfacing on these lists.

[Dan hartung @landgrantdan]

Excited to arrive in a few days! Thank you for the warm welcome!

[Center for Pharmaceutical Policy and Prescribing @PittCP3]

Getting the office ready for our first Visiting Scholar, @landgrantdan, who joins us in less than a week!

[Dan hartung @landgrantdan]

Lilly's goodwill move on Insulin probably easier to stomach as they have possibly the largest blockbuster drug in history on deck in tirzepatide for obesity

https://t.co/5WPDCxWI8P

[Dan hartung @landgrantdan]

@Steven_Hyden This was the first compact disc I ever purchased

[Dan hartung @landgrantdan]

Price of mavenclad (cladribine) highlighted in this article is particularly galling as it had been available for decades as a generic injection and only recently repurosed as oral tabs for $$$$

The Medicine Is a Miracle, but Only if You Can Afford It https://t.co/8eI1FaWjsk

[Dan hartung @landgrantdan]

@bnrome @andrewyorkrx @NASHPhealth Oregon PDAB just released its first report to legislature yesterday. 1st rec is that it be granted authority to set UPL.

https://t.co/YmFJLku7if

[Dan hartung @landgrantdan]

@StefanKertesz Love westerns. Shane and Dead Man are also worthwhile

[Dan hartung @landgrantdan]

One of best things about fall in pnw

[Dan hartung @landgrantdan]

@TheWonkologist @CMSGov @DusetzinaS @peterbachmd @charlesornstein @ProfGenKanter @ki_endoepi @marthpodi @DKorenstein Great news! Will this include all historical data? Propublica offered a cross walk to npi at some point.

[Dan hartung @landgrantdan]

@DusetzinaS Just finished hiking John Muir Trail through sequoia/kings. Despite being "dry" year we experienced week-long storm system that closed whitney portal for several days.

[Dan hartung @landgrantdan]

I celebrated my bday with a five gallon bucket of dehydrated food and energy bars I won't eat. | Find me with inReach➜https://t.co/xaum68geRi

[Dan hartung @landgrantdan]

I'm starting my trip. Follow along at my MapShare site! | Find me with inReach➜https://t.co/7xtqHQmncF

[Dan hartung @landgrantdan]

Our new paper finds large increase in barriers for opioids commonly used for cancer pain in part d.

[Yuhua Bao @yuhuabaophd]

Just out @JCOOP_ASCO. Past 7 years saw several-fold increases in Part D PA and OOP cost for opioids commonly used for cancer pain. @yuhuabaophd @JPaicePhD @landgrantdan @LisaWitkin @HaoZhan51979356 https://t.co/amWnhXJX5q

[Dan hartung @landgrantdan]

Disease modifying therapies account for more than half of all direct medical spending.

[Neurology Journal @GreenJournal]

MS is a costly chronic disease, with direct costs of prescription drugs and indirect productivity loss being important cost drivers. This study's findings suggest the economic burden of #MS in the United States has been underestimated. https://t.co/Z6RSNnps1E #NeuroTwitter

[Dan hartung @landgrantdan]

@choo_ek @RevChuckCurrie See also Ashland OR

[Dan hartung @landgrantdan]

@TheWonkologist Important insights for state Medicaid programs. Unfortunately, the pool of non-conflicted (and conflicted) clinicians with the capacity and desire to serve on these committees can be limited in many states.

[Journal of Studies on Alcohol and Drugs @JSADJournal]

What the Opioid Crisis Took From People in Pain (by @maiasz)
@StefanKertesz @JonahGeddes @gleichtling @KorthuisTodd @landgrantdan @alicia_agnoli @anthony_jerant @fenton_jj @AllysonVarley
https://t.co/pCJyHzk7Vj

[Dan hartung @landgrantdan]

In addition to facing high out-of-pocket costs, individuals with ms and their neurologists often have to deal with utilization management policies (i.e. prior auth) that can compromise care. I was happy to chat about this issue, which was the focus of a recent paper in ncp.

[Neurology Journal @GreenJournal]

Neurology Podcast: On today's episode, you'll hear from Dr. Daniel Hartung (@landgrantdan) on the impact of #MedicarePartD disease-modifying therapy restrictiveness upon adherence and outcomes among patients with #MultipleSclerosis. Listen now! https://t.co/1gycGJHxGd #Neurology